<?xml version='1.0' encoding='utf-8'?>
<document id="25643049"><sentence text="Lack of a pharmacokinetic interaction between trastuzumab and carboplatin in the presence of docetaxel: results from a phase Ib study in patients with HER2-positive metastatic or locally advanced inoperable solid tumors."><entity charOffset="62-73" id="DDI-PubMed.25643049.s1.e0" text="carboplatin" /><entity charOffset="93-102" id="DDI-PubMed.25643049.s1.e1" text="docetaxel" /><pair ddi="false" e1="DDI-PubMed.25643049.s1.e0" e2="DDI-PubMed.25643049.s1.e0" /><pair ddi="false" e1="DDI-PubMed.25643049.s1.e0" e2="DDI-PubMed.25643049.s1.e1" /></sentence><sentence text="The objective of this study was to evaluate the potential for a pharmacokinetic (PK) drug-drug interaction (DDI) between trastuzumab and carboplatin and to evaluate the potential effect of trastuzumab on the electrocardiogram QT interval"><entity charOffset="137-148" id="DDI-PubMed.25643049.s2.e0" text="carboplatin" /></sentence><sentence text=" Here, we report the results of the PK DDI assessment and an interim safety analysis" /><sentence text=" Patients with metastatic or locally advanced, inoperable, human epidermal growth factor receptor 2-positive cancer received docetaxel and carboplatin on cycle 1, day 1 and then on day 1 of each subsequent 3-weekly treatment cycle"><entity charOffset="125-134" id="DDI-PubMed.25643049.s4.e0" text="docetaxel" /><entity charOffset="139-150" id="DDI-PubMed.25643049.s4.e1" text="carboplatin" /><pair ddi="false" e1="DDI-PubMed.25643049.s4.e0" e2="DDI-PubMed.25643049.s4.e0" /><pair ddi="false" e1="DDI-PubMed.25643049.s4.e0" e2="DDI-PubMed.25643049.s4.e1" /></sentence><sentence text=" Trastuzumab was administered by intravenous infusion, with an accelerated loading dose on cycle 1, day 2 and cycle 1, day 8, and then a maintenance dose on day 1 of each subsequent 3-weekly treatment cycle" /><sentence text=" Blood was collected at various time points to assess free (unbound) plasma carboplatin and serum trastuzumab PK"><entity charOffset="76-87" id="DDI-PubMed.25643049.s6.e0" text="carboplatin" /></sentence><sentence text=" The study enrolled 59 patients" /><sentence text=" Carboplatin concentrations in the presence and absence of trastuzumab were similar, as demonstrated by the geometric mean ratios for PK parameters, which were close to 1"><entity charOffset="1-12" id="DDI-PubMed.25643049.s8.e0" text="Carboplatin" /></sentence><sentence text="0 (no effect)" /><sentence text=" The observed trastuzumab concentrations were similar to the values predicted by population PK modelling on the basis of a prediction-corrected visual predictive check, computed using the actual sampling time" /><sentence text=" In this interim safety analysis, 84" /><sentence text="5% of patients had experienced adverse events of grade three or higher, the most common of which were hematologic and as expected" /><sentence text=" The results suggest that there is no clinically relevant PK DDI between carboplatin and trastuzumab"><entity charOffset="73-84" id="DDI-PubMed.25643049.s13.e0" text="carboplatin" /></sentence><sentence text=" The safety profile of trastuzumab plus carboplatin and docetaxel was consistent with the known safety profile of this combination"><entity charOffset="40-51" id="DDI-PubMed.25643049.s14.e0" text="carboplatin" /><entity charOffset="56-65" id="DDI-PubMed.25643049.s14.e1" text="docetaxel" /><pair ddi="false" e1="DDI-PubMed.25643049.s14.e0" e2="DDI-PubMed.25643049.s14.e0" /><pair ddi="false" e1="DDI-PubMed.25643049.s14.e0" e2="DDI-PubMed.25643049.s14.e1" /></sentence><sentence text=" " /></document>